3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
4
Sarcoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Interventions
Paclitaxel
2
Carboplatin
2
selinexor
1
pazopanib
1
Naproxen
1
GX-188 vaccine
1
Filgrastim
1
Educational Status
1
Anesthesia, General
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uterine Diseases
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled